16 December 2021 
EMA/CHMP/684399/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion 1 (post authorisation) 
Lorviqua 
lorlatinib 
On 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Lorviqua. The marketing authorisation holder for this medicinal product is Pfizer Europe MA EEIG. 
The CHMP adopted a new indication as follows: 2 
Lorviqua as monotherapy is indicated for the treatment of adult patients with 
anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer 
(NSCLC) previously not treated with an ALK inhibitor.  
Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK positive 
advanced NSCLC whose disease has progressed after: 
• 
• 
alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or 
crizotinib and at least one other ALK TKI.    
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of  positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days f rom adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Am sterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
